![](http://70.40.205.242/assets/news/GWrskF5y_affymetrix logo.png)
Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Affymetrix Inc (NASDAQ: AFFX) acted responsibly on behalf of investors’ profitability in the planned $1.3 billion sale to Thermo Fisher Scientific Inc (NYSE: TMO).
On January 08, 2016, Affymetrix Inc (NASDAQ: AFFX) and Thermo Fisher Scientific Inc (NYSE: TMO) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Thermo Fisher Scientific will offer Affymetrix shareholders $14.00 per share in cash for all outstanding shares.
Based in Santa Clara, CA, and founded in 1991 Affymetrix Inc provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level.
The investigation focuses on whether NASDAQ: AFFX investors received the highest price and whether the directors of Affymetrix Inc acted in the best interest of Affymetrix Inc company and its shareholders.
If you purchased Affymetrix Inc (NASDAQ: AFFX) prior to January 08, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
by
email: mail@thielerlaw.com
or
telephone at +1 (619) 377 - 4324
or
visit our website http://www.thielerlaw.com/
or
Facsimile: +1 (619) 785 – 3185